Gamma Proteins

Supplier Image

Sanbio, authorized distributor of the Benelux!

Gamma proteins offers high quality and lower cost protein reagents to scientist worldwide.

The initial focus will be on supplying human Fc gamma receptors and FcRn proteins in bulk quantities to worldwide customers through a network of trusted distributors including Sanbio. In the future they intend to follow with pig, rodent and primate Fc gamma receptors and FcRn to have to most complete range of Fc gamma receptor and FcRn recombinant protein products in the future.

All products are available unconjugated and biotinylated.

Product groups for Gamma Proteins

Gamma Proteins was founded in the United Kingdom in 2023 by an experienced entrepreneur and scientist with deep knowledge of recombinant protein expression, purification and quality control as well as the supply of reagents and services to the bio-pharmaceutical industry.

Over the last few decades, recombinant  protein production have gone through a revolution. The rapidly falling cost of DNA sequencing and gene synthesis coinciding with the 100-fold increased productivity by transient mammalian expression procedures, making gram per liter level expression of many proteins routine. Despite these advances the cost of recombinant proteins has risen with microgram of proteins often costing hundreds of dollars.

“Their mission is to deliver substantially lower cost recombinant proteins without compromising on purity and biological activity to enable innovative science,,

Advantages of Gamma Proteins Products

  • High purity >95% by SEC-HPLC
  • Full biological activity confirmed by surface plasmon resonance (SPR)
  • Lower costs
  • Produced from mammalian cells (HEK293)
  • Animal component free
  • Reproducible products; quality and activity confirmed for every batch
  • Low endotoxin (<1 EU / mg)
  • Available unconjugated and site-specific biotinylated
  • Lyophilized for longer stability and reduced environmental impact from transport
  • Inventory in stock at Gamma Proteins
Resources from gamma-proteins
Johnson & Johnson Submits First FDA Application for Nipocalimab to Treat Myasthenia Gravis (MG)